Education
About Us
Working with TipRanks
Follow Us
HeraMED Ltd. (DE:1I4)
FRANKFURT:1I4
1I4 Stock Chart & Stats
€0.02
<€0.01(10.00%)
At close: 4:00 PM EST
€0.02
<€0.01(10.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)152.85K
Market Cap
€26.54M
Enterprise Value€21.73M
Total Cash (Recent Filing)€628.17K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,113,653,400
10 Day Avg. Volume114,978
30 Day Avg. Volume152,848
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.84
Price to Sales (P/S)29.19
P/FCF Ratio-2.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~60% gross margins indicate the product and service mix yields strong unit economics. For a software and connected-device model this margin level supports scalability: if revenue growth resumes, incremental sales can move quickly toward profitability once fixed costs are absorbed.
Improved Balance Sheet And Manageable LeverageRecent restoration of positive equity and a moderate debt-to-equity ratio reduce immediate solvency risk and provide financial flexibility. This improved position helps fund ongoing R&D and commercialization without acute refinancing pressure, supporting operations over the coming quarters.
Focused Digital Women’s Health BusinessA clear product focus on women’s health and remote monitoring aligns with durable structural trends (telehealth, remote clinical workflows). The software plus connected services model supports recurring revenue and clinician integration, which can create long-term customer stickiness if commercial traction improves.
Bears Say
Volatile, Shrinking RevenueA small and declining revenue base undermines operating leverage and makes profitability harder to achieve. A 32% fall in 2024 versus 2023 suggests weak commercial traction; without stable top-line growth, scaling fixed-cost investments in R&D and sales is risky and prolongs the path to breakeven.
Persistent Negative Cash FlowConsistent negative operating and free cash flows, with ~-3.0M of operating cash flow in 2024, show the company burns cash in normal operations. This limits internal funding for growth, increases reliance on external capital, and raises the risk of dilution or constrained investment if markets tighten.
Deep Operating Losses And Negative ReturnsLarge operating losses and strongly negative net margins mean the business currently destroys shareholder capital and registers negative returns on equity. Without sustained revenue recovery or sizeable cost re‑engineering, continued losses will pressure the balance sheet and investor support over time.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is €26.54M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 15 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Aug 28, 2025. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,113,653,400 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in DE:1I4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-513.22%
Trailing 12-Months
Asset Growth
-54.47%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.
Technical Analysis
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Adherium Ltd.
―
InhaleRx Limited
―
Control Bionics Ltd.
―